Paediatric Bone Marrow Transplant (BMT)

When childhood blood or immune diseases are resistant to medication, bone marrow function often declines. If standard treatments fail or bone marrow production becomes ineffective, doctors recommend a Paediatric Bone Marrow Transplant (BMT). This procedure replaces diseased marrow with healthy stem cells and may serve as a primary curative measure for various critical childhood diseases. 

Due to the complexity of the clinical management required throughout the process, BMT necessitates a specialised hospital environment. Success depends on a dedicated paediatric transplant unit capable of providing the intensive care and monitoring essential for recovery during this highly technical medical intervention.

Paediatric Bone Marrow Transplant, also known as stem cell transplantation, replaces unhealthy marrow with healthy blood-forming cells. Bone marrow is the tissue found inside bones that produces red and white blood cells and platelets. BMT is recommended for children when marrow function is impaired or when abnormal cells are produced. 

The objective is to restore normal blood production and reconstruct the immune system. This allows the child's body to resume essential haematological functions that were previously compromised by disease or failure.

There are different types of paediatric BMT:

• Autologous transplant – The child’s own stem cells are gathered, preserved, and returned following a course of high-dose therapy.

• Allogeneic transplant – Stem cells are received from a donor, who may be a sibling, parent, or a matched unrelated donor.

• Haploidentical transplant – A partially matched family donor provides the stem cells for the procedure.

Stem cells may be harvested from bone marrow, peripheral blood, or umbilical cord blood, depending on the medical situation.

Paediatric BMT is a secondary intervention used when standard treatments prove ineffective. It is prescribed only after a thorough clinical appraisal by paediatric specialists, rather than as a routine procedure.

Doctors may recommend paediatric BMT in children with:

• Blood-based cancers, primarily leukaemia or lymphoma

• Aplastic anaemia and marrow failure states

• Genetic blood-forming disorders like sickle cell disease

• Certain inherited immune system failures

• Metabolic conditions affecting the marrow’s production

• Relapsed cancers that demand more aggressive therapy

The procedure may offer the best chance of long-term survival in high-risk cases. In different scenarios, the goal is to improve the patient's daily quality of life and minimise complications.

Transplantation is not the standard for every child with a blood disorder. Selection depends on:

• Disease type and progression

• Previous treatment outcomes

• Donor availability

• Overall physiological health

• Secondary medical complications

The procedure is generally reserved for:

• High-risk or relapsed leukaemia cases

• Patients with chronic transfusion needs

• Children with life-threatening immune failures

• Individuals with severe marrow insufficiency

The pre-treatment phase is intensive. Doctors conduct a series of evaluations, including blood chemistry tests, diagnostic scans, and organ capacity tests. Finally, they conduct donor-matching studies to ensure the transplant has the highest possible chance of success for the young patient.

Paediatric BMT offers life-saving potential, yet specific clinical factors may render the procedure unsuitable for certain patients.

Doctors may delay or reconsider a transplant in children who:

• Have active, uncontrolled infections

• Have severe organ dysfunction affecting the heart, lungs, liver, or kidneys

• Are medically unstable at the time of evaluation

• Do not have an appropriate donor match (in some cases)

In such cases, the medical team may first stabilise the child or explore alternative treatment options before reconsidering transplant.

Paediatric BMT is a carefully planned, multi-step process carried out by a specialised transplant team, including paediatric haematologists, oncologists, nurses, and supportive care specialists.

Before the Transplant

Before transplantation, patients undergo a detailed evaluation. This includes:

• Blood and genetic testing

• Organ function evaluation

• Infection screening

• Donor matching (for allogeneic transplant)

Parents are counselled on associated risks, benefits, expected length of stay, and future monitoring needs.

Conditioning involves chemotherapy and occasionally radiation. This stage is designed to eliminate diseased cells while preparing the bone marrow environment to facilitate the successful engraftment of the newly infused stem cells.

During the Transplant

The transplant is an intravenous infusion of healthy stem cells. These cells relocate to the marrow to generate new blood. While painless and lasting several hours, patient monitoring remains critical.

After the Transplant

Intensive monitoring follows the infusion. Engraftment, the start of blood cell production, takes two to four weeks. In this window:

• Immunity is at a minimum

• Protective isolation is required

• Antibiotics and supportive meds are administered

• Blood counts are checked routinely

Children usually stay in the hospital for three to six weeks. This depends on engraftment and complication management. The stay allows the medical team to verify that the new stem cells are producing healthy blood before the child returns home for further recovery.

Paediatric BMT procedures involve inherent medical risks. Systematic monitoring is implemented to ensure that complications are detected and treated at the earliest stage.

Possible complications include:

• Infection caused by impaired immunity

• Bleeding associated with low platelets

• Organ-specific toxicity from chemotherapy

• Failure or delay in engraftment

• Graft-versus-host disease (GVHD) in allogeneic procedures

• Nutritional insufficiency and fatigue

Some issues happen early; others develop months later. Essential long-term follow-up monitors the child’s growth and organ health. Experienced transplant teams handle serious complications proactively, ensuring the child remains safe and supported while their new system begins to function correctly.

While complex, paediatric BMT delivers major medical benefits:

• Potential cure for various blood cancers

• Correction of underlying genetic blood issues

• Recovery of standard bone marrow performance

• Strengthening of the patient’s immune response

• Decreased necessity for lifelong transfusion support

For many children facing terminal conditions, a transplant provides the best hope for survival and a healthier future.

At Gleneagles Hospitals, paediatric BMT is an integral part of the haematology and oncology programme. The transplant unit supports children who need advanced immune and blood treatments.

Facilities include:

• Specialised transplant rooms with strict infection-control protocols

• Expert paediatric haematologists and oncologists

• Nursing staff trained specifically in transplant care

• On-site laboratory support for donor matching

• Comprehensive blood bank and transfusion services

• Multidisciplinary teams for nutrition, infection, and psychology

A structured follow-up care plan is implemented upon discharge. This professional approach ensures that recovery is monitored and that the medical team addresses long-term health needs.

Paediatric BMT is a specialised procedure used for children with serious blood disorders and cancers. It involves intensive treatment and monitoring but provides potential for a cure. Clinical evaluation and family discussion occur before any procedure. When patients are appropriately selected and receive comprehensive care, they generally tolerate the transplant well. Recovery takes time, leading to an eventual return to normal activities. This structured approach safeguards patient safety while aiming for the most effective long-term health and recovery outcomes.